BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 11218242)

  • 21. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
    Angelberger S; Schaeffeler E; Teml A; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR; Schwab M; Reinisch W
    Inflamm Bowel Dis; 2013 Mar; 19(3):590-8. PubMed ID: 23388543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
    Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
    Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
    Cuffari C; Hunt S; Bayless T
    Gut; 2001 May; 48(5):642-6. PubMed ID: 11302961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azathioprine: state of the art in inflammatory bowel disease.
    Sandborn WJ
    Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological monitoring of azathioprine therapy.
    Reuther LO; Sonne J; Larsen NE; Larsen B; Christensen S; Rasmussen SN; Tofteng F; Haaber A; Johansen N; Kjeldsen J; Schmiegelow K
    Scand J Gastroenterol; 2003 Sep; 38(9):972-7. PubMed ID: 14531535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
    Hanai H; Iida T; Takeuchi K; Arai O; Watanabe F; Abe J; Maruyama Y; Oohata A; Ikeya K; Kageoka M; Miwa I; Yoshirou S; Hosoda Y; Kubota T
    Inflamm Bowel Dis; 2010 Aug; 16(8):1376-81. PubMed ID: 20049951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients.
    Chan GL; Erdmann GR; Gruber SA; Matas AJ; Canafax DM
    J Clin Pharmacol; 1990 Apr; 30(4):358-63. PubMed ID: 2341582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.
    de Beaumais TA; Lorrain S; Mamhoudi N; Simonin M; Martinez Vinson C; Medard Y; Petit A; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2024 Jan; 90(1):209-219. PubMed ID: 37621013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
    Cuffari C; Hunt S; Bayless TM
    Aliment Pharmacol Ther; 2000 Aug; 14(8):1009-14. PubMed ID: 10930894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients.
    Zhu X; Chao K; Li M; Xie W; Zheng H; Zhang JX; Hu PJ; Huang M; Gao X; Wang XD
    World J Gastroenterol; 2019 Oct; 25(38):5850-5861. PubMed ID: 31636477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.
    Park MS; Kim DH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
    Dig Dis Sci; 2015 Jan; 60(1):195-204. PubMed ID: 25239495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy.
    Cuffari C; Li DY; Mahoney J; Barnes Y; Bayless TM
    Dig Dis Sci; 2004 Jan; 49(1):133-7. PubMed ID: 14992447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.
    Achkar JP; Stevens T; Easley K; Brzezinski A; Seidner D; Lashner B
    Inflamm Bowel Dis; 2004 Jul; 10(4):339-45. PubMed ID: 15475740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
    Friedman AB; Brown SJ; Bampton P; Barclay ML; Chung A; Macrae FA; McKenzie J; Reynolds J; Gibson PR; Hanauer SB; Sparrow MP
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1092-1102. PubMed ID: 29468701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
    Wright S; Sanders DS; Lobo AJ; Lennard L
    Gut; 2004 Aug; 53(8):1123-8. PubMed ID: 15247179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
    Kader HA; Wenner WJ; Telega GW; Maller ES; Baldassano RN
    J Clin Gastroenterol; 2000 Jun; 30(4):409-13. PubMed ID: 10875470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
    Gisbert JP; González-Lama Y; Maté J
    Gastroenterol Hepatol; 2006 Nov; 29(9):568-83. PubMed ID: 17129552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
    Thomas CW; Lowry PW; Franklin CL; Weaver AL; Myhre GM; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
    Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.